Literature DB >> 28042555

Lower Extremity Arterial Bypass with Arm Vein Conduits and Literature Review.

Dae-Joon Park1, Yang-Jin Park1, Kyoung Won Yoon1, Seon-Hee Heo1, Dong-Ik Kim1, Young-Wook Kim1.   

Abstract

PURPOSE: The superiority of autogenous vein conduits is well known in lower extremity arterial bypass (LEAB). Among various alternative conduits for LEAB, long-term results of arm vein grafts were investigated in this study.
MATERIALS AND METHODS: We retrospectively reviewed clinical characteristics of 28 patients who underwent infrainguinal LEAB with autogenous arm vein grafts at a single institute between January 2003 and December 2015. All procedures were performed in the absence of adequate saphenous veins. Graft patency was determined by periodic examinations with duplex ultrasonography.
RESULTS: Autologous arm vein grafts were implanted for 28 patients (mean age, 60.4±16.8 years; range, 20-82 years; male, 92.9%; atherosclerosis, 19 [67.9%]; and non-atherosclerotic disease 9 [32.1%] including 5 patients with Buerger's disease). Source of arm vein were basilic 13 (46.4%), cephalic 4 (14.3%) and composition graft with other veins in 11 (39.3%) cases. The level of distal anastomosis was distributed as popliteal in 5 (17.9%), tibio-peroneal in 21 (75.0%) and inframalleolar artery in 2 (7.1%) cases. Mean duration of follow-up was 41.5±46.9 months (range, 1-138 months). Cumulative primary patency rates at 1, 3, and 5 years were 66.5%, 60.9% and 60.9%, respectively. Assisted-primary patency rates at 1, 3 and 5 years were 66.5%, 66.5% and 66.5%, respectively. Secondary patency rates at 1, 3 and 5 years were 70.8%, 70.8% and 70.8%, respectively. There was one limb amputation during the follow-up period.
CONCLUSION: Arm veins are a useful alternative conduit when great saphenous veins are not available during LEAB.

Entities:  

Keywords:  Arm vein; Lower extremity arterial bypass; Result

Year:  2016        PMID: 28042555      PMCID: PMC5198762          DOI: 10.5758/vsi.2016.32.4.160

Source DB:  PubMed          Journal:  Vasc Specialist Int        ISSN: 2288-7970


INTRODUCTION

With widespread use of endovascular interventions for patients with leg artery occlusive disease, lower extremity arterial bypasses (LEAB) are decreasingly being used. However, LEAB is still the most durable treatment option. The superiority of autogenous vein conduits to prosthetic grafts is well accepted in LEAB, particularly in distal leg bypass. It has been reported that ipsilateral great saphenous vein (GSV) is regarded as the first choice conduit for lower limb bypass [1-6]. However up to 20%–45% of patients requiring bypass surgery do not have an available GSV in both extremities due to inadequate size, length, or prior usage [7,8]. The alternative autogenous conduits include the small saphenous vein (SSV), basilic or cephalic arm veins, inferior epigastric artery and composite vein [8,9]. The objective of this study was to present the long-term results of arm vein graft in LEAB.

MATERIALS AND METHODS

Study design, patient, and data collection

This retrospective study included twenty-eight patients who underwent infrainguinal LEAB with autogenous arm vein graft due to the absence of adequate saphenous vein graft from January 2003 to December 2015 at Samsung Medical Center, Seoul, Korea. This study was approved by the Institutional Review Board of Samsung Medical Center (No. smc-2016-12-094) and the patients’ consents were waived. Arm vein was used for 12 initial procedures and for 16 revision procedures of previous bypass grafts and/or endovascular procedures. Assessment of vein availability and its quality was performed by vein mapping with preoperative routine duplex ultrasonography. The saphenous vein was considered unusable if it was too small (<2 mm) or occluded due to thrombus on duplex ultrasonography. Therefore, if preoperative scan showed that bilateral saphenous veins were not suitable for bypass in all patients, arm veins were scanned for bypass conduit with duplex ultrasonography. Arm veins were regarded as suitable vein grafts when the measured diameters were at least 2 mm. Vein mapping was performed by registered vascular technologists marking the courses of cephalic and/or basilic veins from the wrist to the axillary fossa. All LEAB patients with arm vein grafts underwent duplex ultrasonography to evaluate graft patency at postoperative 1, 6, 12 months and every 6 to 12 months thereafter. This study used definitions and classification of all criteria as those recommended by the Ad Hoc Committee on Reporting Standards appointed by the Society of Vascular Surgery and the North American chapter of the International Society of Cardiovascular Surgery [10].

Statistical analysis

Primary, primary-assisted, secondary patency and limb salvage rates were calculated using the Kaplan-Meier method. Log-rank test was used to examine differences between each group. Student’s t-test was used to compare continuous variables. Statistical analysis was performed with IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). P-values of <0.05 were considered as statistically significant.

RESULTS

Patient characteristics

Mean age of patients was 60.4 years and 92.9% of patients were male. Twenty cases (71.4%) of arm vein bypass were performed for limb salvage of the patients with critical limb ischemia (Rutherford category 4 and 5) and 8 (28.6%) for the patients with severe claudication (Rutherford category 3). The reasons for absence of GSV are listed as follows: 14 patients (50.0%) had undergone previous bypass procedures, 12 patients (42.9%) had inadequate GSV size or length and 2 patients (7.1%) had thrombus in their GSVs (Table 1).
Table 1.

Patient characteristics (n=28)

CharacteristicNo. of grafts
Age (y)60.4±16.8 (20–82)
Male26 (92.9)
Etiology
  Atherosclerosis19 (67.9)
  Non-atherosclerotic disease9 (32.1)
    Buerger’s disease5 (17.9)
    Chronic embolic occlusion1 (3.6)
    Othersa3 (10.7)
Indication
  Rutherford category 38 (28.6)
  Rutherford category 48 (28.6)
  Rutherford category 512 (42.9)
  Non-healing ulcer3 (10.7)
  Gangrene9 (32.1)
Prior treatment (n=16)
  Leg bypass14
  Endovascular intervention9
Comorbidity
  Diabetes mellitus9 (32.1)
  Hypertension13 (46.4)
  Ischemic heart disease8 (28.6)
  Smoking10 (35.7)
  Hyperlipidemia9 (32.1)

Values are presented as mean±standard deviation (range), number (%), or number only.

Popliteal artery entrapment syndrome, iatrogenic femoral injury, popliteal artery aneurysm.

The bypass grafts were composed of single arm vein segments in 17 cases (60.7%) and composite veins in 11 cases (39.3%) (Table 2). The most common inflow artery was the common femoral artery (11 cases, 39.3%) and most common outflow arteries were the anterior tibial and posterior tibial arteries (8 cases each, 28.6%) (Table 3).
Table 2.

Graft source (n=28)

Source of arm veinGrafts (n, %)
Cephalic vein4 (14.3)
Basilic vein13 (46.4)
Composite vein11 (39.3)
Basilic vein+cephalic vein composition7 (25.0)
Basilic vein+great saphenous vein or small saphenous vein composition4 (14.3)
Table 3.

Anatomic configuration of bypass procedure

Anastomosis level (n=28)Grafts (n, %)
ProximalCommon femoral artery11 (39.3)
SFA10 (35.7)
Popliteal artery5 (17.9)
Other vein graft2 (7.1)
DistalAbove knee popliteal artery/SFA2 (7.1)
Below knee popliteal artery3 (10.7)
Tibio-peroneal trunk1 (3.6)
Anterior tibial artery8 (28.6)
Posterior tibial artery8 (28.6)
Peroneal artery4 (14.3)
Dorsalis pedis artery1 (3.6)
Infra-malleolar posterior tibial artery1 (3.6)

SFA, superficial femoral artery.

Morbidity and mortality

The overall perioperative morbidity was reported in 4 patients (14.3%). It included acute myocardial infarction (n=1, 3.6%), stroke (n=2, 7.1%), and postoperative bleeding (n=1, 3.6%), while no morbidity was associated with the arm vein harvest procedure in our study. The 30-day mortality rate was 0%. During the mean follow-up period of 41.5±46.9 month (range, 1–138 months), 3 patients (10.7%) died from combined medical illness of cerebral hemorrhage, gastrointestinal bleeding, and aspiration pneumonia.

Graft patency and limb salvage

The 1-year primary, assisted-primary and secondary patency rates were 66.5%±10.5%, 66.5%±10.5% and 70.8%±10.2%, respectively. Five-year primary, assisted-primary and secondary patency rates were 60.9%±11.0%, 66.5%±10.5% and 70.8%±10.2%, respectively (Fig. 1). There was one limb amputation after bypass during the follow-up and 5-year limb-salvage rate was 94.4%±5.4%.
Fig. 1.

Patency of lower extremity arterial bypass with arm vein conduits. (A) Primary patency. (B) Assisted-primary patency. (C) Secondary patency.

There was no significant difference in graft patency and limb salvage rate between single arm vein segment grafts and composite arm vein grafts. Five-year secondary patency of single arm vein segment graft and composite vein graft were 69.4%±12.1% and 71.4%±17.1% (P=0.78), respectively (Fig. 2).
Fig. 2.

Patency of single segment and composite vein graft. Five-year secondary patency of single segment arm vein graft and composite vein graft were not statistically significant (69.4%±12.1% vs. 71.4%±17.1%, P=0.78).

DISCUSSION

The first study of lower limb bypass with arm vein conduit was reported in 1969 [11]. After that, several studies from the past decade have introduced good long term patency rates and limb salvage rates in lower limb bypass with arm vein conduit [8,12-16]. Some groups have encouraged the use arm veins as the first alternative conduit when the ipsilateral GSV is absent due to the low morbidity of arm vein harvesting and for preservation of the contralateral GSV [8,12,13]. These studies showed that contralateral GSVs were subsequently used for either contralateral infrainguinal limb bypass (20%–23%) or coronary bypass (2%–3%). Recent studies have reported that LEAB using arm vein conduits showed 3-year graft patency and limb salvage rates ranging from 40% to 73% and 63% to 92%, respectively [8,12,13,16]. In our series, the overall 3-year patency and limb salvage rates were 60.9% and 94.4%, respectively. These results are comparable to other previous studies. Despite the above evidence supporting the efficacy of arm vein grafts in patients with LEAB, it remains an infrequently used procedure because of concerns about the need to make composite veins in some patients to obtain adequate length. This has been considered a limitation to the use of arm vein graft as the venovenostomy has been shown to negatively affect the patency of these grafts [15]. However our study shows no negative effect on patency or limb salvage rate of composite vein grafts compared to single segment grafts. We preferred basilic veins to cephalic veins as graft source. In our study, only 4 cephalic vein grafts were used for bypass. The cephalic vein is often inadequate for conduit due to prior puncture or trauma. Some authors suggest that the location of the basilic vein limits its utility as vascular access for hemodialysis and is thus less likely to be traumatized or can be avoided for venous puncture compared to the cephalic vein [17]. Arm veins or polytetrafluoroethylene (PTFE) grafts with adjunctive procedures could be considered as alternative bypass conduits when all saphenous veins are inadequate for LEAB bypass [18]. Previous studies showed that results from infrapopliteal bypass using prosthetic graft have been less satisfactory than those obtained with arm vein (Table 4) [8,12,16,19-25]. In our institute, we prefer arm vein graft as a first choice of alternative graft in infrapopliteal bypass in the absence of adequate saphenous vein. In our study, subanalysis of infrapopliteal arm vein bypasses (23 cases) showed that 3-year primary patency, secondary patency, and limb salvage rates were 50.5%, 63.3%, 92.9%, respectively. By comparison, a meta-analysis of PTFE infrapopliteal bypass published in 2003 introduced 3-year primary patency, secondary patency, and limb salvage rates of 41%, 51%, and 66%, respectively [18]. The above results suggest that the arm vein is a favorable alternative conduit in infrapopliteal bypass when no saphenous veins are available.
Table 4.

Literature review of infrapopliteal bypass with arm vein or prosthetic graft

StudyLimbs no.2–3 years patency rates (%)2–3 years limb salvage rates (%)


Arm veinProstheticArm veinProsthetic
Veith et al., 1986 [20]981261
Quiñones-Baldrich et al., 1992 [21]282237
Parsons et al., 1996 [22]663971
Jakobsen et al., 1998 [23]395075
Wijesinghe et al., 1998 [24]505180
Faries et al., 2000 [12]5541.163.2
Arvela et al., 2010 [16]16010.457.1
Calligaro et al., 1997 [19]512671
Hölzenbein et al., 1996 [8]25051.991.4
Faries et al., 2000 [12]17468.381.4
Arvela et al., 2010 [16]13056.875.0
Calligaro et al., 1997 [19]284676
Linni et al., 2015 [25]325287.5
This study2870.894.4
The present study has several limitations. First, this study was a retrospective design and there could be some selection bias in the patients. Second, it was composed of small sample size, by which statistical power might be weak, although it is the largest case series reported in Korea. At last, there is no comparison group such as infrapopliteal bypass using prosthetic graft, so we presented some literature review and compared indirectly with several previous studies.

CONCLUSION

Our results showed that the arm vein was a useful alternative conduit when great or SSV was not available during LEAB. In case of short length of vein, composite vein grafts are also a reliable conduit.
  25 in total

1.  In situ saphenous vein arterial bypass for infrainguinal revascularization: initial experience using an open technique.

Authors:  A V de Mello; C M Santos; J L Silva; M T Souza; M A Portilho; A V Guimarães; R G Freitas; J W Silvério
Journal:  Int Angiol       Date:  1991 Jul-Sep       Impact factor: 2.789

2.  Recommended standards for reports dealing with lower extremity ischemia: revised version.

Authors:  R B Rutherford; J D Baker; C Ernst; K W Johnston; J M Porter; S Ahn; D N Jones
Journal:  J Vasc Surg       Date:  1997-09       Impact factor: 4.268

3.  In situ saphenous vein bypass for occlusive disease in the lower extremity.

Authors:  D M Rogers; E L Rhodes; J S Kirkland
Journal:  Surg Clin North Am       Date:  1986-04       Impact factor: 2.741

Review 4.  Experiences with in situ lower extremity saphenous vein bypass procedures.

Authors:  R P Leather; D M Shah
Journal:  Surg Annu       Date:  1988

5.  Infrainguinal reconstruction with arm vein, lesser saphenous vein, and remnants of greater saphenous vein: a report of 257 cases.

Authors:  G L Londrey; L P Bosher; P W Brown; F D Stoneburner; J W Pancoast; R K Davis
Journal:  J Vasc Surg       Date:  1994-09       Impact factor: 4.268

6.  Arm vein conduit vs prosthetic graft in infrainguinal revascularization for critical leg ischemia.

Authors:  Eva Arvela; Maria Söderström; Anders Albäck; Pekka-Sakari Aho; Maarit Venermo; Mauri Lepäntalo
Journal:  J Vasc Surg       Date:  2010-07-07       Impact factor: 4.268

7.  Use of arm and lesser saphenous vein compared with prosthetic grafts for infrapopliteal arterial bypass: are they worth the effort?

Authors:  K D Calligaro; J R Syrek; M J Dougherty; I Rua; C A Raviola; D A DeLaurentis
Journal:  J Vasc Surg       Date:  1997-12       Impact factor: 4.268

8.  Optimizing infrainguinal arm vein bypass patency with duplex ultrasound surveillance and endovascular therapy.

Authors:  Paul A Armstrong; Dennis F Bandyk; Jeffrey S Wilson; Murray L Shames; Brad L Johnson; Martin R Back
Journal:  J Vasc Surg       Date:  2004-10       Impact factor: 4.268

9.  Meta-analysis of polytetrafluoroethylene bypass grafts to infrapopliteal arteries.

Authors:  Maximiano Albers; Vinicius Marcus Battistella; Marcello Romiti; Alfredo Augusto Eyer Rodrigues; Carlos Alberto Bragança Pereira
Journal:  J Vasc Surg       Date:  2003-06       Impact factor: 4.268

10.  Polytetrafluoroethylene (PTFE) femorodistal grafts with a distal vein cuff for critical ischaemia.

Authors:  L D Wijesinghe; D M Beardsmore; D J Scott
Journal:  Eur J Vasc Endovasc Surg       Date:  1998-05       Impact factor: 7.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.